Electromed earnings release, May 12, 2026
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026
Third
Quarter
18% Revenue growth and strong operating leverage exceeds consensus expectations for the third quarter of fiscal 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)-- Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and nine months ended March 31, 2026
(“
Q3
FY
2026”).
Q3
FY
2026
Company Highlights
“I'm happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth. Electromed's unique business model created to address the underserved airway clearance market is achieving the desired results we had expected,” said Jim Cunniff, President and Chief Executive Officer. “We continue to make investments in our sales and fulfillment teams to drive greater prescription volumes and faster delivery of our SmartVest therapy to more patients. With 86% of covered lives in the United States now under contract and our manufacturing optimization complete, we're well-positioned to capture the opportunity in the underserved bronchiectasis market. As we look ahead, our strong operational foundation, strategic investments, and continued focus on education and awareness give us confidence in sustaining our trajectory of profitable growth."
Q3
FY
2026
Results
All amounts below are for the three months ended
March 31, 2026, and compare to the three months ended
March 31, 2025
(“
Q3
FY
2025”).
Net revenues grew
18.4% to $
18.6 million, from $
15.7 million.
Revenue in our direct homecare business increased by
18.6% to $
16.7 million, from $
14.1 million. The increase in revenue was primarily due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per sales representative. Throughout
Q3 FY 2026, we averaged⁵⁷ homecare direct field sales representatives. The annualized homecare revenue per weighted average direct sales representative in
Q3
FY
2026 was $1,168,000, exceeding Electromed’s target range for the year of $1,000,000 to $1,100,000.
Non-homecare revenue was $
1.8 million. Hospital revenue grew
42.5%, totaling $
1.0 million. Homecare distributor revenue was $
0.7 million, an increase of
2.7%. Other revenue of $
0.1 million declined
40.7%.
Gross profit increased year-over-year to $
14.6 million or
78.8% of net revenues from $
12.2 million or
78.0% of net revenues. The increases in gross profit and gross margin were primarily a result of increased overall revenue and higher net revenues per device.
Selling, general and administrative (“SG&A”) expenses were $
10.5 million, representing an increase of $
0.7 million or
7.2%. The increase in the current period was primarily due to the increased salaries and incentive compensation related to the higher average sales representative headcount and higher overall compensation costs.
Operating income was $
3.8 million or
20.3% of net revenues, compared to $
2.1 million, or
13.6% of net revenues. The
76.0% increase in operating income was primarily due to the increases in revenue and gross profit.
Net income increased by
58.8% to $
3.0 million, or $
0.35 per diluted share, compared to $
1.9 million, or $
0.21 per diluted share.
As of
March 31, 2026, Electromed had $
17.0 million in cash, $
28.3 million in accounts receivable and no debt, achieving a working capital of $
40.0 million and total shareholders’ equity of $
49.2 million. The cash balance reflects an increase of $
1.7 million for the nine months ended March 31, 2026, compared to a decrease in cash of $
0.8 million in the nine months ended March 31, 2025. The increase in cash for the nine months ended March 31, 2026, was driven primarily by positive operating cash flow of $6.7 million, partially offset by share repurchases of $
3.9 million of Electromed common stock.
Conference Call and Webcast Information
The conference call with members of Electromed management will be held at 5:00 p.m. Eastern Time on Tuesday, May 12, 2026.
Interested parties may participate in the call by dialing (877) 407-3982 (Domestic) or (201) 493-6780 (International).
The live conference call webcast will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: https://viavid.webcasts.com/starthere.jsp?ei=1759896&tp_key=ae965d6622
For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Domestic) or (412) 317-6671 (International) and referencing the Access ID 13760099. Additionally, an online replay of the webcast will be available for one year in the Investor Relations section of Electromed’s web site at: https://investors.smartvest.com/events-and-presentations/default.aspx
About Electromed, Inc.
Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com.
Financial statements
Income Statement
Three Months Ended — Condensed Statements of Operations (Unaudited)
| Three Months Ended – March 31, – 2026 | Three Months Ended – March 31, – 2025 | Nine Months Ended – March 31, – 2026 | Nine Months Ended – March 31, – 2025 | ||
|---|---|---|---|---|---|
| Net revenues | 18,575,000 | 15,684,000 | 54,359,000 | 46,607,000 | |
| Cost of revenues | 3,932,000 | 3,455,000 | 11,700,000 | 10,260,000 | |
| Gross profit | 14,643,000 | 12,229,000 | 42,659,000 | 36,347,000 | |
| Operating expenses | Selling, general and administrative | 10,516,000 | 9,812,000 | 31,617,000 | 29,033,000 |
| Operating expenses | Research and development | 361,000 | 277,000 | 986,000 | 694,000 |
| Operating expenses | Total operating expenses | 10,877,000 | 10,089,000 | 32,603,000 | 29,727,000 |
| Operating expenses | Operating income | 3,766,000 | 2,140,000 | 10,056,000 | 6,620,000 |
| Operating expenses | Interest income, net | 100,000 | 142,000 | 343,000 | 489,000 |
| Operating expenses | Net income before income taxes | 3,866,000 | 2,282,000 | 10,399,000 | 7,109,000 |
| Operating expenses | Income tax expense | 863,000 | 391,000 | 2,499,000 | 1,776,000 |
| Operating expenses | Net income | 3,003,000 | 1,891,000 | 7,900,000 | 5,333,000 |
| Income per share: | Basic | 0.37 | 0.22 | 0.96 | 0.63 |
| Income per share: | Diluted | 0.35 | 0.21 | 0.91 | 0.59 |
| Weighted-average common shares outstanding: | Basic | 8,211,220 | 8,495,005 | 8,268,605 | 8,493,715 |
| Weighted-average common shares outstanding: | Diluted | 8,647,794 | 8,967,838 | 8,673,345 | 8,980,218 |
Balance Sheet
March 31, 2026 — Condensed Balance Sheets
| March 31, 2026 – (Unaudited) | June 30, 2025 | ||
|---|---|---|---|
| Current Assets | Cash and cash equivalents | 16,985,000 | 15,287,000 |
| Current Assets | Accounts receivable (net of allowances for credit losses of $45,000) | 28,251,000 | 24,660,000 |
| Current Assets | Contract assets | 1,086,000 | 1,036,000 |
| Current Assets | Inventories | 3,295,000 | 3,299,000 |
| Current Assets | Income tax receivable | 15,000 | 408,000 |
| Current Assets | Prepaid expenses and other current assets | 596,000 | 392,000 |
| Current Assets | Total current assets | 50,228,000 | 45,082,000 |
| Current Assets | Property and equipment, net | 5,209,000 | 4,714,000 |
| Current Assets | Finite-life intangible assets, net | 354,000 | 371,000 |
| Current Assets | Other assets | 1,221,000 | 1,173,000 |
| Current Assets | Deferred income taxes | 2,462,000 | 2,462,000 |
| Current Assets | Total assets | 59,474,000 | 53,802,000 |
| Current Liabilities | Accounts payable | 2,595,000 | 2,667,000 |
| Current Liabilities | Accrued compensation | 4,530,000 | 5,079,000 |
| Current Liabilities | Warranty reserve | 1,784,000 | 1,645,000 |
| Current Liabilities | Other accrued liabilities | 1,317,000 | 1,077,000 |
| Current Liabilities | Total current liabilities | 10,226,000 | 10,468,000 |
| Current Liabilities | Other long-term liabilities | 81,000 | 125,000 |
| Current Liabilities | Total liabilities | 10,307,000 | 10,593,000 |
| Shareholders' Equity | Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,279,845 and 8,349,176 shares issued and outstanding, as of March 31, 2026, and June 30, 2025, respectively | 83,000 | 83,000 |
| Shareholders' Equity | Additional paid-in capital | 23,949,000 | 21,941,000 |
| Shareholders' Equity | Retained earnings | 25,135,000 | 21,185,000 |
| Shareholders' Equity | Total shareholders' equity | 49,167,000 | 43,209,000 |
| Shareholders' Equity | Total liabilities and shareholders' equity | 59,474,000 | 53,802,000 |
Cash Flow
Nine Months Ended March 31, — Condensed Statements of Cash Flows (Unaudited)
| Nine Months Ended March 31, – 2026 | Nine Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Cash Flows From Operating Activities | Net income | 7,900,000 | 5,333,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Depreciation | 642,000 | 663,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Amortization | 162,000 | 112,000 |
| Adjustments to reconcile net income to net cash provided by operating activities: | Share-based compensation expense | 1,960,000 | 2,409,000 |
| Changes in operating assets and liabilities: | Accounts receivable | -3,591,000 | -109,000 |
| Changes in operating assets and liabilities: | Contract assets | -50,000 | -405,000 |
| Changes in operating assets and liabilities: | Inventories | -123,000 | 564,000 |
| Changes in operating assets and liabilities: | Prepaid expenses and other assets | -364,000 | -779,000 |
| Changes in operating assets and liabilities: | Income tax receivable, net | 393,000 | -1,209,000 |
| Changes in operating assets and liabilities: | Accounts payable and accrued liabilities | 291,000 | 877,000 |
| Changes in operating assets and liabilities: | Accrued compensation | -549,000 | 78,000 |
| Changes in operating assets and liabilities: | Net cash provided by operating activities | 6,671,000 | 7,534,000 |
| Cash Flows From Investing Activities | Expenditures for property and equipment | -1,033,000 | -117,000 |
| Cash Flows From Investing Activities | Expenditures for finite-life intangible assets | -44,000 | -32,000 |
| Cash Flows From Investing Activities | Net cash used for investing activities | -1,077,000 | -149,000 |
| Cash Flows From Financing Activities | Issuance of common stock upon exercise of options | 268,000 | 381,000 |
| Cash Flows From Financing Activities | Taxes paid on net share settlement of stock awards | -246,000 | -2,278,000 |
| Cash Flows From Financing Activities | Repurchase of common stock | -3,918,000 | -6,331,000 |
| Cash Flows From Financing Activities | Net cash used for financing activities | -3,896,000 | -8,228,000 |
| Cash Flows From Financing Activities | Net increase (decrease) in cash | 1,698,000 | -843,000 |
| Cash and cash equivalents | Beginning of period | 15,287,000 | 16,080,000 |
| Cash and cash equivalents | End of period | 16,985,000 | 15,237,000 |
Full release
Cautionary Statements... (truncated)ssociated with such statements. Examples of risks and uncertainties for Electromed include, but are not limited to, our ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products; component or raw material shortages, changes to lead times or significant price increases and changes to trade regulations (including, but not limited to, changes to tariffs); adverse changes to state and federal health care regulations; our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances; entry of new competitors including new drug or pharmaceutical discoveries; adverse economic and business conditions or intense competition; wage and component price inflation; technical problems with our research and products; the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats; changes affecting the medical device industry; our ability to develop new sales channels for our products such as the hospital or homecare distributor channels; adverse international health care regulation impacting current international business; our ability to renew our line of credit or obtain additional credit as necessary; and our ability to protect and expand our intellectual property portfolio, as well as other factors we may describe from time to time in Electromed’s reports filed with the Securities and Exchange Commission (including Electromed’s most recent Annual Report on Form 10-K, as amended from time to time, and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K). Investors should not consider any list of such factors to be an exhaustive statement of all the risks, uncertainties or potentially inaccurate assumptions investors should take into account when making investment decisions. Shareholders and other readers should not place undue reliance on “forward-looking statements,” as such statements speak only as of the date of this press release. We undertake no obligation to update them in light of new information or future events.
Brad Nagel, Chief Financial Officer
(952) 758-9299 investorrelations@electromed.com
Mike Cavanaugh, Investor Relations
ICR Healthcare
(617) 877-9641 mike.cavanaugh@icrhealthcare.com
Source: Electromed, Inc.
Electromed, Inc.
Condensed Balance Sheets
Electromed, Inc.
Condensed Statements of Operations (Unaudited)
Electromed, Inc.
Condensed Statements of Cash Flows (Unaudited)